Hyperthermic Intraperitoneal Chemotherapy in Interval Debulking Surgery for Advanced Epithelial Ovarian Cancer: A Single-Center, Real-Life Experience
Hyperthermic Intraperitoneal Chemotherapy in Interval Debulking Surgery for Advanced Epithelial Ovarian Cancer: A Single-Center, Real-Life Experience
复制标题
DOI：
10.1002/cncr.33167
复制
发表时间：
2020-09-15
期刊：
影响因子：
6.2
通讯作者：
Fagotti, Anna
中科院分区：
文献类型：
--
作者：
Ghirardi, Valentina;Ronsini, Carlo;Fagotti, Anna
背景技术背景：最近的一项随机对照试验证实，在间隔减瘤手术（IDS）后接受热腹腔化疗（HIPEC）治疗的晚期上皮性卵巢癌患者的生存率得到改善，而围手术期发病率没有增加。本研究旨在评估在转诊癌症中心IDS后使用HIPEC的可行性和围手术期结局。方法：在研究期间，进行了149个IDS。至少患有国际妇产科联合会III期疾病的患者，
BACKGROUND: An improvement in survival without increasing perioperative morbidity in patients with advanced epithelial ovarian cancer treated with hyperthermic intraperitoneal chemotherapy (HIPEC) after interval debulking surgery (IDS) has been recently demonstrated in a randomized controlled trial. This study was aimed at assessing the feasibility and perioperative outcomes of the use of HIPEC after IDS at a referral cancer center. METHODS: Over the study period,149 IDSs were performed. Patients who had at least International Federation of Gynecology and Obstetrics stage III disease, with